
NeurologyLive® Friday 5 — January 16, 2026
Key Takeaways
- Proposed revisions to NMOSD diagnostic criteria were discussed by Shailee Samir Shah, MD, at ECTRIMS 2025, emphasizing significant updates.
- Brian Lin, PhD, highlighted advances in ALS research, focusing on genetics, biomarkers, and clinical trial readiness ahead of the 2026 MDA Conference.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Click the read more buttons for more details and information about each highlight.
1: Sharing Key Updates Proposed for Revised NMOSD Diagnostic Criteria: Shailee Samir Shah, MD
In a recent interview, Shailee Samir Shah, MD, clinical assistant professor at Feinberg School of Medicine, outlined some of the major revisions proposed for the NMOSD diagnostic criteria presented at ECTRIMS 2025. [WATCH TIME: 8 minutes]
2: Enhancing ALS Care Through Genetics, Biomarkers, and Clinical Trial Readiness: Brian Lin, PhD
Ahead of the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, Brian Lin, PhD, research portfolio director at the MDA, spoke about ongoing advances in ALS research and how they may inform approaches to therapeutic development. [WATCH TIME: 5 minutes]
3: Collaborating Across Global Borders to Improve Understanding of Parkinson Disease: Samia Ben Sassi, MD
At the 2025 MDS Congress, Samia Ben Sassi, MD, the professor of neurology at University Tunis El Manar, described the role of global collaboration in advancing the understanding, diagnosis, and management of Parkinson disease. [WATCH TIME: 6 minutes]
4: NeuroVoices: Nicholas Ashton, PhD, on Advances and Challenges in Alzheimer Disease Biomarkers
In our latest NeuroVoices Q&A, Nicholas Ashton, PhD, the senior director of the Fluid Biomarker Program at Banner Health, highlighted the evolving role of blood and fluid biomarkers in Alzheimer disease research and clinical practice.
5: Using Digital Multidomain Lifestyle Interventions for Alzheimer Disease Prevention: Tatsuhiro Hisatsune, PhD
At the 2025 CTAD Conference, Tatsuhiro Hisatsune, PhD, associate professor at The University of Tokyo, talked about how lifestyle-focused multidomain interventions, including exercise, sleep, and nutrition, may improve cognitive function. [WATCH TIME: 4 minutes]
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.



























